Press Releases

Press Releases

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


IVI acquires $6.46-million grant to measure single dose impact of HPV vaccine

2018-05-14 04:42
The International Vaccine Institute (IVI), a Seoul, Korea-based nonprofit international organization devoted to new vaccines, has acquired a 6.46 million-dollar grant from the Bill & Melinda Gates Foundation to conduct a Human papillomavirus (HPV) vaccine single-dose impact study in Thailand.  The study will be conducted in partnership with the Thailand Ministry of Public Health and proposes to measure the effectiveness of a single-dose of HPV vaccine administered to young women in Thailand, while also generating data of single dose effectiveness to inform global public health policy. IVI will receive a total of $6,465,516 from the foundation for this study through October 2023.

HPV is the most common viral infection of the reproductive tract. Some HPV strains are harmless but others cause cervical cancer, with HPV infection responsible for nearly all cases of cervical cancer. According to the World Health Organization, globally, cervical cancer is the fourth most common cancer in women with an estimated 530,000 new cases in 2012 alone, and accounts for 7.5 percent of all female cancer deaths. It is estimated that more than 270,000 die from cervical cancer yearly, with over 85 percent of these deaths occurring in less developed regions.

There are currently two internationally licensed HPV vaccines: Gardasil® and Cervarix®. Both vaccines are shown to be safe and very effective in preventing infection with HPV 16 and 18, which are known to cause at least 70 percent of all cervical cancers. By mid-2016, 65 countries had introduced HPV vaccines, including a growing number of middle- and low-income countries. Both vaccines are administered in a two- or three-dose regimen, which can be costly.

“Data of single dose effectiveness can be highly useful in informing the most cost-effective approach to HPV vaccination and global public health policy,” said Dr. Julia Lynch, Deputy Director General for Development and Delivery at IVI, who will lead the study. “If one dose is confirmed to offer sufficient protection, it could significantly reduce vaccine and administration costs while increasing uptake to save more lives.”

About International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to discovery, development and delivery of safe, effective and affordable vaccines for global public health. Established in 1997 as an initiative of the United Nations Development Program, IVI operates as a nonprofit, independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, South Korea. For more information, please visit